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Participants: 23 and 12 non asthmatic males and females 
 
 
Design: Blind, Randomised, Counter balanced training study 
 
 
Treatment groups:  
 
¥  Salmeterol  (SAL)   100µg  (2 x 50µg twice daily)  n=12 
¥  Formoterol  (FOR)    12µg  (2 x 6µg twice daily)  n=12    
¥  Placebo  (PLA)               (2 x twice daily)   n=11 
	
AIM OF THE STUDY 
Investigate the ergogenic effect of 5 weeks daily inhalation of long 
acting β2-Agonists on Sprint performance. 
Week	0	 Week	6	
30 mt Sprint 30 mt Sprint Strength and Power  
Training 
30m Sprint was greater 5 weeks post training in FOR 
(p=0.049) and SAL (p=0.040) compared to PLA. 
 
 Week 0 Week 5 
SAL 7.38 ± 0.74 s	 7.03 ± 0.72 s	
FOR  7.10 ± 0.70 s	 6.81 ± 0.74 s	
PLA 7.40 ± 1.33s	 7.40 ± 1.23 s	
Table	1:	Change	in	30	m	
sprint	from	week	0	to	week	5		
Figure	1:	Change	in	30	m	sprint	from	week	0	to	week	5	
CONCLUSION 
	
	
	
	
	
¥  Sprint	improvement	observed	over	5	weeks	did	not	
diﬀer	between	SAL	and	FOR	groups.	However,	FOR	
and	SAL	showed	a	signiﬁcant	improvement	in	sprint	
performance	when	compared	with	PLA	following	the	
5	weeks	of	strength	training.	
¥  SAL	and	FOR	may	increased	anaerobic	ATP	uΜlizaΜon,	
elevated	glycolyΜc	acΜvity	and	enhanced	rates	of	Ca2+	
release	and	uptake	from	the	sarcoplasmic	reΜculum.	
¥  Future	research	should	invesΜgate	potenΜal	
mechanisms	to	explain	our	results.	
